Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label …

…, CM Korse, RJ van Klaveren, FMNH Schramel… - The Lancet …, 2013 - thelancet.com
Background Standard chemotherapy does not lead to long-term survival in patients with
malignant pleural mesothelioma. Malignant pleural mesothelioma is strongly dependent on …

[HTML][HTML] Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands

…, M Tonn, BJM Peters, FMNH Schramel… - Scientific Reports, 2021 - nature.com
This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness)
correspond to outcomes in clinical trials (efficacy) and to look into factors that might …

[HTML][HTML] Decision support systems for incurable non-small cell lung cancer: a systematic review

…, EG Engelhardt, JJ Tamminga, FMNH Schramel… - BMC medical informatics …, 2017 - Springer
Background Individually tailored cancer treatment is essential to ensure optimal treatment
and resource use. Treatments for incurable metastatic non-small cell lung cancer (NSCLC) …

Videothoracoscopic appearance of first and recurrent pneumothorax

JP Janssen, FMNH Schramel, TG Sutedja, MA Cuesta… - Chest, 1995 - Elsevier
Study objective Comparison of the videothoracoscopic appearance of first and recurrent
pneumothorax, and assessment of a relation between endoscopic appearance and recurrence …

Atmospheric pressure changes and outdoor temperature changes in relation to spontaneous pneumothorax

HJM Smit, WL Devillé, FMNH Schramel, AJM Schreurs… - Chest, 1999 - Elsevier
Study aims To examine the influence of atmospheric pressure (AP) and temperature changes
on the incidence of idiopathic spontaneous pneumothorax (SP). Methods From December …

Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer

…, BJM Peters, FMNH Schramel… - European …, 2018 - Eur Respiratory Soc
The divergence between clinical trial results and real-world outcomes is largely unknown for
many cancer types. The present study aims overall to assess the efficacy–effectiveness gap …

Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial

…, MJJH Grootenboers, FMNH Schramel… - The Annals of Thoracic …, 2004 - Elsevier
… with MN combined with pulmonary metastasectomy is feasible. Dose-limiting toxicity occurred
at a dose of 60 mg of MN at 37C, and the maximum tolerated dose was set at 45 mg of MN

Evaluation of serum biomarker CEA and Ca-125 as immunotherapy response predictors in metastatic non-small cell lung cancer

…, BJM Peters, H Kelder, FMNH Schramel - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Treatment options for advanced non-small cell lung cancer (NSCLC) include
immunotherapy. Elevated carcinoembryonic antigen (CEA) and cancer antigen 125 (Ca-…

Clinical outcomes in early-stage NSCLC treated with stereotactic body radiotherapy versus surgical resection

…, M Van Vulpen, FMNH Schramel - Anticancer …, 2015 - ar.iiarjournals.org
Background: Surgical resection is the treatment of first choice for patients with stage I-II non-small
cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) has been …

[HTML][HTML] Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases

…, J Braun, H Gelderblom, FMNH Schramel… - Journal of thoracic …, 2014 - Elsevier
Introduction The 5-year overall survival rate of patients undergoing complete surgical resection
of pulmonary metastases (PM) from colorectal cancer (CRC) and sarcoma remains low (…